LY-03. Long-term multicenter study of nivolumab efficacy and safety in patients with relapsed and refractory classic Hodgkin lymphoma

Cellular Therapy and Transplantation

article

Yaroslava V. Komarova¹  Ludmila V. Fedorova¹  Marina V. Demchenkova²  Maria V. Grigorieva²  Polina V. Kotselyabina¹  Andrey M. Chekalov¹  Elena E. Lepik¹  Elena V. Kondakova¹  Evgenia S. Borzenkova¹  Vadim V. Baykov¹  Marina O. Popova¹  Ivan S. Moiseev¹  Kirill V. Lepik¹  Natalia B. Mikhailova¹  Alexander D. Kulagin¹ 

[1] RM Gorbacheva Research Institute, Pavlov University;Regional Oncological Clinic

关键词: Nivolumab;    PD-1 inhibitors;    immunotherapy;    Hodgkin lymphoma;    LYRIC criteria.;   

DOI  :  10.18620/ctt-1866-8836-2022-11-3-1-132

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

Nivolumab (Nivo) showed its efficacy in patients with relapsed and refractory classic Hodgkin lymphoma (r/r cHL) in clinical trials. Continued accumulation of the long-term experience in PD-1 inhibitors treatment is required to support previous data. Our aim was to evaluate long-term data on the efficacy and safety of Nivo therapy in patients with r/r cHL.

【 授权许可】

CC BY